文献速递前列腺癌男科与性医学

接受雄激素剥夺治疗的前列腺癌男性合并症发展:澳大利亚人群队列研究

Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-05-02

该回顾性队列研究利用澳大利亚PBS 10%数据,分析2004至2010年间首次接受雄激素剥夺治疗的前列腺癌男性,并与年龄性别匹配的对照组比较九种合并症的发生风险。结果显示,治疗组心血管疾病、抑郁、糖尿病、胃酸相关疾病、高脂血症、骨质疏松及疼痛/炎症的风险显著升高,而反应性气道疾病和阿尔茨海默病无显著差异。

要点

  • 接受ADT的前列腺癌男性新发心血管疾病、抑郁、糖尿病等合并症风险显著高于对照组。
  • 心血管疾病和抑郁的风险比在治疗第一年最高,随后随时间下降。
  • 结果支持需要建立协调照护模式以管理前列腺癌幸存者的多种慢性病。

核心结论

  • 接受雄激素剥夺治疗的前列腺癌男性比未接受该治疗者更可能发生新的合并症。

研究设计与样本

  • 前列腺癌队列为2004至2010年间首次接受雄激素剥夺治疗的男性。
  • 对照组为年龄和性别匹配、研究期间未使用抗肿瘤药物且基线无特定合并症者,按1:10比例匹配。

主要发现

  • 前列腺癌队列发生心血管疾病的风险比为1.37(95% CI: 1.26-1.48),高于对照组。
  • 抑郁风险比为1.86(95% CI: 1.73-2.01),糖尿病为1.30(95% CI: 1.15-1.47)。
  • 胃酸相关疾病风险比为1.48(95% CI: 1.39-1.57),高脂血症为1.18(95% CI: 1.09-1.29)。
  • 骨质疏松风险比为1.65(95% CI: 1.48-1.85),疼痛/炎症为1.47(95% CI: 1.39-1.55)。
  • 反应性气道疾病和阿尔茨海默病在两组间无显著差异。

临床怎么用

  • 对接受雄激素剥夺治疗的前列腺癌患者,应关注心血管疾病、抑郁、糖尿病、骨质疏松等合并症的筛查与管理。
  • 治疗早期(第一年)尤其需警惕心血管疾病和抑郁的发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The increasing use of androgen deprivation therapy has prompted further evaluation of its potential adverse effects as the treatment may exacerbate or increase the risk of developing new comorbid diseases. This study aims to assess the patterns of comorbidities among Australian men with prostate cancer treated with androgen deprivation therapy. METHODS: Pharmaceutical Benefits Scheme (PBS) 10% data between 1 January 2003 and 31 December 2014 was utilised in this retrospective cohort study. Men who had received their first androgen deprivation therapy between 2004 and 2010 were selected as the prostate cancer cohort. Comorbidities were identified using the dispensing claims data and classified with the Rx-Risk-V model. Comparisons were made between the prostate cancer cohort and specific control groups (age-matched and sex-matched without any dispensing of anti-neoplastic agents during the study period and without the individual comorbidity of interest evaluated at baseline at 1:10 ratio) for the development of nine individual comorbidities over time using Cox regression models. RESULTS: The prostate cancer cohort had a significant higher risk of developing cardiovascular conditions (hazard ratio 1.37, 95% CI: 1.26-1.48), depression (1.86, 95% CI: 1.73-2.01), diabetes (1.30, 95% CI: 1.15-1.47), gastric acid disorders (1.48, 95% CI: 1.39-1.57), hyperlipidaemia (1.18, 95% CI: 1.09-1.29), osteoporosis (1.65, 95% CI: 1.48-1.85) and pain/pain-inflammation (1.47, 95% CI: 1.39-1.55) compared to the control groups. The hazard ratios for cardiovascular conditions and depression were highest in the first year and declined over time. There were no significant differences between the two groups for reactive airway diseases and Alzheimer's disease. CONCLUSION: Men with prostate cancer treated with androgen deprivation therapy had a higher likelihood of developing new comorbidities than men who did not receive androgen deprivation therapy. Our results support the need for developing coordinated care models that effectively address multiple chronic diseases experienced by prostate cancer survivors.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Ng HS, Koczwara B, Roder D, et al. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Prostate Cancer Prostatic Dis. 2018. PMID: 29720722. doi:10.1038/s41391-018-0036-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。